Altimmune, Inc.

Today, we published our fourth quarter & full year 2024 financial results. Learn more about our recent business highlights and our upcoming virtual R&D Day: https://lnkd.in/erBS-5av. Tune in to our webcast today at 8:30 a.m. ET: https://bit.ly/4gUPYL6.

Today, we announced the expansion of our Board of Directors with the appointments of Jerry Durso and Teri Lawver. Their diverse backgrounds and deep, multi-disciplinary expertise further enhance our board presence and will help guide the continued execution of our strategic vision as we accelerate our pipeline and bring our promising therapeutic to patients in need. ? Learn more in the full release: https://lnkd.in/gNerrkHY.

We are looking forward to attending the J.P. Morgan Healthcare Conference in San Francisco next week to engage with industry leaders who share our commitment to innovation and patient impact! Connect with us to learn more about #pemvidutide, our #GLP1/ #glucagon dual receptor agonist for #obesity and #MASH. #JPM25

Tomorrow, our Chief Medical Officer,?M. Scott Harris, M.D., will be onsite at the Global Cardiovascular Clinical Trialists Forum in Washington, D.C. to join other industry experts for a panel discussion exploring the latest results from anti-obesity clinical trials and their cardiovascular implications for patient care and future research.? ? Join him to learn more about how recent findings are paving the way for improved treatment options, starting with our lead candidate #pemvidutide, a #GLP1/ #Glucagon dual receptor agonist for the treatment of #obesity. Learn more:?https://bit.ly/4f4lHIM. ? ? CVCT - Cardiovascular Clinical Trialists ? #CVCT2024?

#ICYMI Our Chief Executive Officer, Dr. Vipin Garg, joined CNBC’s “Fast Money” to share Altimmune’s progress, vision and future developments surrounding our lead candidate #pemvidutide, a #GLP1/#Glucagon dual receptor agonist for the treatment of #obesity and MASH.?? ? Learn more about how our recent progress supports the potential of pemvidutide to redefine treatment outcomes for obesity patients, particularly by reducing inflammatory lipids associated with negative cardiovascular outcomes and preserving lean mass critical for physical health and quality of life. Watch the interview here and below:?https://bit.ly/4fhfz05?

This week, our Chief Medical Officer, M. Scott Harris, M.D., will be presenting body composition data from the Phase 2 MOMENTUM trial of #pemvidutide in the treatment of #obesity and participating in a panel discussion at the Society on Sarcopenia, Cachexia and Wasting Disorders Regulatory & Trials Update Workshop in Washington, D.C. Learn more in our latest release: https://bit.ly/4eWw69w? ? #SCWD2024?

Next week, members of our executive team will be participating in #firesidechats at the Evercore and Piper Sandler Healthcare Conferences. Read the press release below for additional details, and connect with us onsite for 1x1 meetings: https://lnkd.in/e_UxsuvD.

Today, we presented new data from our 12-week Phase 1b trial of #pemvidutide in metabolic dysfunction-associated steatotic liver disease (#MASLD) at The Liver Meeting of the?American Association for the Study of Liver Diseases (AASLD). Learn more about our new findings in the full release: https://lnkd.in/edbR7HwX. ? #TLM24?

We’re proud to sponsor this year’s MetALD Conference in San Diego and be a part of conversations around the opportunities & challenges in #clinical drug development as we continue to advance innovative therapeutics for patients with #metabolic dysfunction-associated liver diseases. Register for the event here: https://bit.ly/3CboUsn?

Today, we provided a corporate update and published our third quarter 2024 financial results. Learn more about our recent business highlights, including completion of enrollment in the Phase 2b IMPACT trial of pemvidutide in #MASH and a successful End-of Phase 2 meeting with the FDA for pemvidutide in the treatment of #obesity: https://lnkd.in/gcu4SyhD